Bayer increases women’s access to modern contraception, promotes benefits of less cases of maternal deaths, unwanted pregnancies, child mortality

March 15, 2022

While pursuing research to find new treatment options for gynecological diseases with a high unmet medical need, Bayer is also working on addressing women’s health needs during menopause.

   For more than 50 years, Bayer has supported educational programs and rights-based family planning in more than 130 countries, particularly by increasing access to modern forms of contraception.

   In 2019, Bayer pledged to provide 100 million women in low-and-middle-income countries with access to family planning by 2030.

    This initiative is part of Bayer’s comprehensive set of sustainability measures and commitments and in line with the United Nations Sustainable Development Goals (UN SDGs) .

   “We believe every girl and woman deserves the chance to determine her own future. That’s why Bayer is partnering with local and international organizations, such as the United Nations Population Fund and the United States Agency for International Development, to empower women to make informed decisions about family planning,” said Mildred Nadah Pita, Head of Global Healthcare Programs/Sustainability Middle Africa at Bayer.

   “With Bayer’s commitment to provide 100 million women in low- and middle-income countries with access to modern contraception by 2030, we are making an important contribution to achieving the UN Sustainable Development Goals by improving the health, rights and economic status of women around the world, which is a fundamental prerequisite for greater equality, education and prosperity for all.”

   As part of this commitment, Bayer recently announced an investment of over €400 million in new production facilities for long-acting reversible contraceptives, including the construction of a new production site in Alajuela, Costa Rica and the expansion of production capabilities in Turku, Finland.

Shaping women’s health from menarche to menopause

  Elinzanetant, a non[1]hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause.

   “Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally. With increased longevity, maintaining functional ability and good quality of life is extremely relevant from both a healthcare and a socio-economic perspective. Unfortunately, menopause remains a taboo topic, leaving many women untreated,” said Cecilia Caetano, MD, Head of Medical Affairs Menopause at Bayer.    

   “With our strong heritage and deeply rooted expertise in women’s health, we continue to focus on providing innovative science, solutions and education to support the individual health need of women.”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.